On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Provides Update on CBD Patent Formulas

Company: Earth Science Tech, Inc. (ETST)
Category: News

Earth Science Tech (OTC: ETST), an innovative biotech company focused on the cannabidiol (“CBD”), nutraceutical and pharmaceutical fields, this morning issued a release detailing the progression of the company’s CBD IP patent formula development program. The company is currently developing three new CBD formulas, one of which is a new type of superfood with unique organoleptic properties that is formulated from a mix of hemp oil and other vegetable oil(s) and enriched with a highly potent antioxidant. This product is designed to improve the individual’s antioxidant ingestion. The remaining two unique CBD formula products are comprised of a neuron protector and a breast protector which both proved very promising in R&D performed by the Centre de développement bioalimentaire du Québec (“CDBQ”) or Quebec Agrifood Innovation Center (“QAIC”). Additionally, the company has two products in development as part of a joint venture with Bionatus Laboratório Botânico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc. “We are already at work with Bionatus in Brazil and in Canada on the manufacture of the first product, Propovit enriched with ETST hemp oil. We are also working on a reformulation of Bionatus’ product,” ETST CEO and Chief Science Officer, Dr. Michel Aube stated in the news release. “The new formulation will see the product enriched with CBD to boost the suspected anti-inflammatory and bronchial-dilatation properties of the main natural ingredient – Guaco (Mikania glomerata) extract.”

To view the full press release, visit http://nnw.fm/Bydu0

About Earth Science Tech, Inc.

Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, and studies through DV Biologics prove it lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217